Companies

NOVAVAX INC (NVAX) SEC filings

CIK 0001000694 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31

Annual financials (from the company's own XBRL in its 10-K filings)

FY2025FY2024FY2022FY2021
Revenue (USD)1.1 B2.0 B
Net income (USD)-418.3 M-132.7 M
Diluted EPS (USD/shares)2.58-8.42

Latest filings

FiledFormDescriptionPeriod
2026-10-16SCHEDULE 13GSCHEDULE 13G
2026-10-16SCHEDULE 13D/ASCHEDULE 13D/A
2026-08-07SCHEDULE 13GSCHEDULE 13G
2026-08-06S-8FORM S-8
2026-08-068-K8-K items 2.02,9.012026-08-06
2026-08-0610-Q10-Q2026-06-30
2026-06-234OWNERSHIP DOCUMENT2026-06-18
2026-06-234OWNERSHIP DOCUMENT2026-06-18
2026-06-234OWNERSHIP DOCUMENT2026-06-18
2026-06-234OWNERSHIP DOCUMENT2026-06-18
2026-06-234OWNERSHIP DOCUMENT2026-06-18
2026-06-234OWNERSHIP DOCUMENT2026-06-18
2026-06-234OWNERSHIP DOCUMENT2026-06-18
2026-06-234OWNERSHIP DOCUMENT2026-06-18
2026-06-238-KFORM 8-K items 5.072026-06-18
2026-05-27144144
2026-05-15SCHEDULE 13D/ASCHEDULE 13D/A
2026-05-07144144
2026-05-068-K8-K items 2.02,9.012026-05-06
2026-05-0610-Q10-Q2026-03-31
2026-04-30SCHEDULE 13GSCHEDULE 13G
2026-04-284OWNERSHIP DOCUMENT2026-04-25
2026-04-27SCHEDULE 13G/ASCHEDULE 13G/A
2026-04-27ARSARS2025-12-31
2026-04-27DEFA14ADEFA14A

Forms on file (last 1,000): 4 478, 8-K 204, 10-Q 41, SC 13G/A 41, DEFA14A 20, 424B5 20, 3 19, S-8 15. Source: SEC EDGAR, as filed; this page is public data and not investment advice.

For software and AI agents: the same data as JSON, per call, no account: GET https://store.agentexchange.work/gw/filings/company?ticker=NVAX (0.002 USD), /gw/filings/filings?ticker=NVAX&form=8-K, /gw/filings/facts?ticker=NVAX&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txt

Updated from EDGAR within 30 minutes of a filing. Agent Exchange